• Vaccine Name: SARS-CoV N protein DNA vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: N (Shi et al., 2006)
• nucleocapsid protein (N) gene of SARS-CoV gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)
• Description: DNA vaccine made from recombinant plasmid containing nucleocapsid protein (N) sequence constructed then expressed and purified from E. coli bacteria (Shi et al., 2006)

Mouse Response

• Vaccination Protocol: DNA-coated gold particles were prepared and delivered to the shaved abdominal regions of mice using a helium-driven gene gun (Bio-Rad) with a discharge pressure of 400 lb/in2. C57BL/6 mice were immunized with 2 μg of the plasmid encoding N protein. The mice received two boosters with the same dose at a 1-week interval. (Kim et al., 2004)
• Immune Response: Significantly increased neutralizing antibody titer to N protein DNA vaccine and significantl count of INF-gamma CD8_ lymphocytes within splenocytes (Kim et al., 2004)
• Challenge Protocol: Challenge Protocol: Vaccinated mice challenged with DNA encoding N and challenged these mice with Vac-N or Vac-WT (Recombinant vaccinnia virus expressing SARS N protein or wild-type vaccinia virus, respectively) intranasally or intravenously 1 week after the last vaccination (Kim et al., 2004)
• Efficacy: reduced viral titer load(Kim et al., 2004)

Mouse Response

• Host Strain: Balb/c (Shi et al., 2006)
• Vaccination Protocol: 20 μg of vaccine intramuscular injection (Shi et al., 2006)
• Immune Response: Production of N-specific IgG antibodies (paricularly IgG2a), Lymphocyte proliferation, Production of IFN-γ, IL-2, IL-4, Increased CD4+ and CD8+ levels
  (Shi et al., 2006)

Vole Response

• Host Strain: Microtus brandti raddes (Shi et al., 2006)
• Vaccination Protocol: 100 μg injected (Shi et al., 2006)
• Immune Response: increased N-specific antibodies, increased lymphocye proliferation specific to N antigen (Shi et al., 2006)
• Challenge Protocol: 100 μg injected three times at an interval of 7 days and then challenged with live SARS-CoV (PUMC01) (Shi et al., 2006)